BioVersys’ goal is to switch-off antibiotic resistances were they are first occurring and therefore expanding the lifetime of existing FDA-licensed antibiotics. Our profound understanding of the genetics behind bacterial resistanc...
See More e mechanisms enables us to recognize the pathways, which are activated once resistant bacterial strains come into contact with an antibiotic. At this point our patented compounds interfere with the activation of the “bacterial defense” program, so that the original antibiotic will kill the bacteria.